American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
Publication year
2010Author(s)
Source
Archives of Pathology & Laboratory Medicine, 134, 6, (2010), pp. 907-22ISSN
Annotation
01 juni 2010
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Laboratory of Genetic, Endocrine and Metabolic Diseases
Journal title
Archives of Pathology & Laboratory Medicine
Volume
vol. 134
Issue
iss. 6
Page start
p. 907
Page end
p. 22
Subject
IGMD 6: Hormonal regulation; ONCOL 5: Aetiology, screening and detection; Laboratory Medicine Radboud University Medical CenterAbstract
PURPOSE: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. METHODS: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. RESULTS: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. RECOMMENDATIONS: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.
This item appears in the following Collection(s)
- Academic publications [245350]
- Faculty of Medical Sciences [93207]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.